Current Investments
- Affinium Pharmaceuticals Inc.http://www.afnm.com/
Affinium is a structure-guided drug discovery company pioneering the discovery of new medicines through proprietary knowledge of proteins and chemistry. The company's proprietary, integrated drug discovery process is designed for rapid advancement of small molecule programs from gene to clinic.
- Allostera Pharma Inc.http://www.allostera.com/
Allostera Pharma Inc. is a platform based biopharmaceutical company. It is developing a novel class of peptide therapeutics that modulate their targets in an allosteric manner. The company's current indication focus is in the fields of autoimmune and inflammatory disorders.
- Epocal Inc.http://www.epocal.com/
Epocal's core expertise and enabling technologies are in the field of biochip nanotechnology. The company's biochips combine aspects of two powerful analytical technologies of the current state of the art, lab-on-a-chip microfluidic technology and microarray technology, into a more powerful integrated technology: solid-state fluidics.
- NeurAxon Inc.http://www.nrxn.com/
NeurAxon Inc.is a CNS drug discovery company with an initial focus on poorly treated areas of pain potentially amenable to treatment with drugs aimed at validated but as yet unexploited targets. As such NeurAxon will utilise its unique IP and expertise in drug design and application.
- Profound Medical Inc.http://www.profoundmedical.com
Profound Medical Inc., founded in June 2008, is a privately-held medical device company dedicated to developing a novel treatment for Prostate Cancer; delivering the fastest, least-invasive, and highest Quality-of-Life outcomes for patients of the disease.
- Tioga Pharmaceuticals, Inc.http://www.tiogapharma.com/
Tioga Pharmaceuticals, Inc., founded in 2005, is focused on the development of novel therapies for the treatment of gastrointestinal diseases. Tioga's lead compound, asimadoline, is currently in clinical development for the treatment of irritable bowel syndrome (IBS).